home / stock / rnxt / rnxt news

RNXT News and Press, RenovoRx Inc.

Stock Information
Company Name: RenovoRx Inc.
Stock Symbol: RNXT
Market: NASDAQ
Website: renovorx.com
Menu
RNXT RNXT Quote RNXT Short RNXT News RNXT Articles RNXT Message Board
Get RNXT Alerts

News, Short Squeeze, Breakout and More Instantly...
RNXT - RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

LOS ALTOS, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today annou...
RNXT - University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...

RNXT - RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...

RNXT - RenovoRx CEO Issues Update Letter to Shareholders

With $17.2 million in gross proceeds raised since the beginning of 2024, RenovoRx is well positioned to advance its pivotal Phase III clinical trial, expand development pipeline into additional cancer indications and explore new commercial business development opportunities with its therapeutic t...
RNXT - Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP(TM) Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

Data shows that the Trans-Arterial Micro-Perfusion (TAMP) platform increases intra-arterial pressure, improving drug delivery with 100-fold increase local tissue concentration of the therapy TAMP offers the potential to increase efficacy, improve safety and widen therapeutic window of dru...

RNXT - RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, Chief Executive Officer, will part...

RNXT - RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024

RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun R. Bagai, Chief Executive Officer, will p...
RNXT - RenovoRx files to sell 6.96M shares of common stock for holders

2024-04-26 17:18:23 ET More on RenovoRx RenovoRx closes $6.1M private placement Seeking Alpha’s Quant Rating on RenovoRx Historical earnings data for RenovoRx Financial information for RenovoRx Read the full article on Seeking Alpha For...

RNXT - RenovoRx regains compliance with Nasdaq

2024-04-18 08:41:47 ET More on RenovoRx RenovoRx closes $6.1M private placement Seeking Alpha’s Quant Rating on RenovoRx Read the full article on Seeking Alpha For further details see: RenovoRx regains compliance with Nasdaq

RNXT - RenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement

RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that, in light of its recent successful fundraising ac...
Next 10